Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Dr. Eileen Hsich is the Director of the Women’s Heart Failure clinic and Associate Medical Director for the Heart Transplant Program at the Cleveland Clinic. She specializes in heart failure in women, heart transplantation, and nuclear cardiology.
Dr. Hsich received her medical degree from The Johns Hopkins University School of Medicine and completed her cardiology fellowship at Tufts-New England Medical Center (NEMC) in Boston. She did cardiovascular basic science research both at the National Institutes of Health (NIH) and Tufts- New England Medical Center where she received the National Research Service Award for Individual Postdoctoral Fellows. She was appointed to The Cleveland Clinic in 2004 after completing her clinical training in heart failure/ heart transplantation at Massachusetts General Hospital in Boston. In 2006, she was appointed Assistant Professor of Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Hsich has published in many high impact journals. Her research interests center on sex differences in heart failure management and clinical outcome. She uses institutional and national databases to explore these topics. She has also served as the co-principal investigator on multi-center clinical trials.
Dr . Hsich is a member of American Heart Association, American College of Cardiology, American Society of Nuclear Cardiology, International Society for Heart & Lung Transplant, and Heart Failure Society of America.
Cardiomyopathy, cardiac tumors, heart failure, heart transplantation, ventricular assist device, heart failure in women
Awards & Honors
AHA grant awarded for creating a model to predict survival in ambulatory women and men with severe systolic heart failure
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland
Clinic's procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. The Cleveland Clinic requires its doctors to approve the public disclosures of their scientific collaborations with industry. As of 8/31/2014 the review process regarding Dr. Hsich's disclosure had not been completed. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.